Natural HIV-1 controllers maintain low plasma HIV RNA levels in the absence of antiretroviral therapy (ART) and represent a model for functional cure mechanisms. The study summarized here quantified multiple HIV DNA regions and distinct classes of HIV RNA transcripts in longitudinal blood samples to determine how HIV transcription and reservoir measures differ between natural controllers and ART-suppressed noncontrollers, and to assess whether ART further alters HIV DNA or RNA in controllers.
The analysis used blood samples collected longitudinally from 10 natural controllers (five categorized as "elite" and five as "viremic") sampled before ART and then up to 3–5 years while on suppressive ART. These controller data were compared with samples from ART-suppressed noncontrollers. The abstract does not provide the exact number of noncontrollers, detailed inclusion criteria, or full assay protocols; those details are available only in the full text.
Investigators measured a range of HIV DNA regions and quantified intact proviruses. Compared to ART-suppressed noncontrollers, natural controllers demonstrated lower levels of most measured HIV DNA regions. However, the level of intact proviruses was not reduced in controllers relative to noncontrollers according to the abstracted results. This pattern suggests a reduced frequency of infected cells in controllers for many genomic regions but not a measurable reduction in intact proviral burden as assessed in the reported assays.
The study quantified multiple classes of HIV transcripts reflecting different stages of transcriptional progression: initiated transcripts, 5' elongated transcripts, completed transcripts, and multiply spliced transcripts. Total levels of initiated and completed HIV RNA were lower in controllers than in noncontrollers, consistent with a smaller overall transcriptional burden in controllers.
When transcript levels were normalized to proviral burden (per provirus), controllers unexpectedly showed higher levels of initiated and 5' elongated HIV transcripts per provirus. Conversely, controllers exhibited a lower ratio of completed to elongated transcripts and, after ART, lower multiply spliced RNA and a reduced multiply spliced/completed RNA ratio. These findings point to a relative accumulation of short or prematurely terminated transcripts per provirus in controllers with reduced progression to completion and splicing.
Key contrasts between groups reported in the abstract:
Controllers had lower levels of most measured HIV DNA regions than noncontrollers, but not lower counts of intact proviruses.
Total initiated and completed HIV RNA were lower in controllers versus noncontrollers.
Per provirus, controllers had higher levels of initiated and 5' elongated transcripts, indicating more frequent short transcription events per infected cell.
Controllers had a lower ratio of completed/elongated RNA, consistent with reduced progression from early elongation to full-length transcript production.
After ART, controllers showed lower multiply spliced HIV RNA and a lower multiply spliced/completed RNA ratio compared with noncontrollers.
In controllers who started and remained on suppressive ART, the study reported further increases in CD4+ T-cell counts and decreases in total HIV DNA and in some HIV RNA transcripts over the 3–5 year follow-up. These longitudinal changes suggest that ART confers additional immunologic and reservoir reductions even in individuals who previously controlled viremia without therapy.
The reported data support a two-part model for natural control: (1) reduced infection frequency resulting in lower total HIV DNA and lower absolute levels of many transcripts, and (2) a selective limitation on transcriptional completion and splicing such that a higher proportion of proviruses produce short, prematurely terminated transcripts while fewer proviruses produce completed and spliced RNAs. These latter features could reflect host or viral mechanisms that block transcriptional progression or preferential clearance of cells producing completed and spliced transcripts.
The observed further CD4+ T-cell gains and decreases in HIV DNA/RNA after ART initiation in controllers support offering ART to natural controllers. Even when plasma viremia is controlled without therapy, ART may provide additional immunologic benefit and reduce reservoir measures.
The abstract summarizes cohort composition (10 controllers, five elite and five viremic) and principal findings but does not report the number of ART-suppressed noncontrollers, detailed assay methods, statistical testing, or exact quantitative values and confidence measures. Full-method descriptions, exact cohort sizes for the comparator group, and numerical results are not included in the abstract and require consultation of the full article for comprehensive appraisal.
Natural HIV controllers display a smaller overall HIV DNA burden and lower total HIV RNA levels than ART-treated noncontrollers, yet show relatively elevated short transcript production per provirus and decreased progression to completed and spliced transcripts. ART given to controllers yielded further immunologic and reservoir benefits, supporting offering ART to this population.